The Real-World Impact of Risankizumab on the Quality of Life and Cumulative Life Course Impairment (CLCI) in Patients With Moderate-to-Severe Plaque Psoriasis (DREAM)
The Real-World Impact of Risankizumab on the Quality of Life and Cumulative Life Course Impairment (CLCI) in Patients With Moderate-to-Severe Plaque Psoriasis (DREAM)
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study will assess the change in quality of life of risankizumab treatment in adult participants with moderate to severe plaque psoriasis real-world clinical practice.
Risankizumab is an approved drug for treating participants with Psoriasis. Approximately 700 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately 70 sites worldwide.
Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 2.5 years.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Inclusion Criteria:
Exclusion Criteria:
julieta.gonzalezblanco@abbvie.com844-663-3742
Calgary, Alberta T2J 7E1, Canada
Prague, Central Bohemia 180 81, Czechia
Friedrichshafen, Baden-Wurttemberg 88046, Germany
Mölln, Schleswig-Holstein 23879, Germany
Leipzig, 04317, Germany
Thessaloniki, 54643, Greece
Thessaloniki, 54643, Greece
L’Aquila, L Aquila 67100, Italy
Rome, Roma 00168, Italy
Asahikawa-shi, Hokkaido 078-8510, Japan
Kyoto, Kyoto 602-8566, Japan
Ginowan-shi, Okinawa 901-2725, Japan
Sakai-shi, Osaka 590-0197, Japan
Suita-shi, Osaka 565-0871, Japan
Bunkyo-ku, Tokyo 113-8431, Japan
Shinjuku-ku, Tokyo 161-8521, Japan
Osaka, 550-0006, Japan
Cartagena, Murcia 30203, Spain
El Palmar, Murcia 30120, Spain
+420 377 534 145